Minimally Invasive Surgery Market: as Intuitive Surgical’s worldwide da Vinci installed base surpasses 11,000 systems and da Vinci 5 placements more than double year over year, the robotic-assisted segment of minimally invasive surgery is completing its transition from a differentiated, premium option into the default capital equipment expectation for any hospital seeking to remain competitive for complex surgical referrals, so the market’s growth increasingly depends less on convincing hospitals robotic assistance is worthwhile and more on how quickly credentialing, reimbursement, and training infrastructure can keep pace with accelerating installed base expansion.

The global minimally invasive surgery market size was USD 96.28 Billion in 2025 and is expected to register a revenue CAGR of 7.8% during the forecast period. Market revenue growth is driven by factors such as the accelerating expansion of the worldwide robotic-assisted surgical system installed base, the more than doubling of da Vinci 5 system placements year over year signalling accelerating replacement and expansion capital investment, and continued CMS reimbursement policy expansion supporting robotic-assisted procedures at ambulatory surgical centres. The first driving factor is the accelerating expansion of the worldwide robotic-assisted surgical system installed base, extending robotic-assisted minimally invasive surgery capability to a growing number of hospitals globally. Intuitive Surgical’s worldwide da Vinci installed base reached 11,106 surgical systems as of December 31, 2025, a 12% increase from 9,902 systems a year earlier, reflecting sustained double-digit installed base growth. The second driving factor is the more than doubling of da Vinci 5 system placements year over year, signalling accelerating hospital capital investment in the newest-generation robotic-assisted surgical platform specifically. Intuitive Surgical placed 870 da Vinci 5 systems during 2025, more than double the 362 da Vinci 5 systems placed during 2024, reflecting accelerating hospital adoption of the newest-generation platform beyond simply replacing ageing prior-generation systems. The third driving factor is continued reimbursement policy expansion supporting robotic-assisted procedures at ambulatory surgical centres, extending robotic-assisted minimally invasive surgery beyond traditional hospital inpatient settings. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way an expanding robotic-assisted surgical system installed base widens its own addressable procedure volume as each newly placed system ramps toward mature utilisation over its operating life, letting cumulative installed base growth compound into procedure volume and consumable demand well beyond what new system placement revenue alone captures in any single year. Once a robotic surgical system is placed at a hospital, procedure volume on that system typically grows for several years as surgical teams gain experience and expand the range of procedures performed robotically, so each year’s installed base growth compounds into rising procedure volume for years afterward rather than generating its full revenue impact immediately, meaning cumulative installed base and long-run procedure volume are directly linked with a multi-year lag. As a result, demand and revenue share are concentrating around markets and manufacturers with the largest, most mature installed bases capable of generating sustained procedure volume growth, and the forecast tilts toward robotic-assisted surgery capturing an increasing share of overall minimally invasive procedure volume rather than robotic and conventional laparoscopic approaches growing at comparable rates. For instance, in January 2026, Intuitive Surgical, United States, reported a da Vinci installed base of 11,106 surgical systems as of December 31, 2025, representing 12% year-on-year installed base growth, with da Vinci procedure volume reaching approximately 3,153,000 for the year, an 18% increase, illustrating how a compounding installed base translates into procedure volume growth that outpaces the installed base growth rate itself as more of that base matures toward full utilisation. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained, double-digit expansion of the worldwide robotic-assisted surgical system installed base. A larger installed base directly expands the population of hospitals capable of offering robotic-assisted minimally invasive surgery, and since procedure volume on each system grows over its operating life as surgical teams gain experience, a growing installed base compounds into rising procedure volume well beyond the year in which each system was placed, so installed base growth and multi-year procedure volume growth are directly and structurally linked. Intuitive Surgical’s worldwide da Vinci installed base reached 11,106 surgical systems as of December 31, 2025, a 12% increase from 9,902 systems as of December 31, 2024, according to the company’s January 2026 earnings release. The effect on the market is that robotic-assisted minimally invasive surgery capability continues to extend to a growing population of hospitals, expanding the addressable procedure volume base for both capital equipment and recurring instrument revenue. These are some of the key factors driving revenue growth of the market.

The second driver is the more than doubling of da Vinci 5 system placements year over year, a pace of acceleration well beyond what typical system replacement cycles alone would generate. A placement pace that more than doubles year over year indicates hospitals are not simply replacing ageing prior-generation systems on a fixed replacement cycle, but are actively expanding total robotic-assisted surgical capacity, and this distinction matters because expansion capital investment signals genuinely growing procedure demand rather than steady-state utilisation, so da Vinci 5’s placement acceleration and genuine capacity expansion, not just replacement, are directly linked. Intuitive Surgical placed 870 da Vinci 5 systems during 2025, more than double the 362 da Vinci 5 systems placed during 2024, out of 1,721 total da Vinci systems placed globally during the year. The recent record shows the pace. The fourth quarter of 2025 alone included 303 da Vinci 5 placements out of 532 total da Vinci systems placed, compared with 174 da Vinci 5 placements out of 493 total systems in the fourth quarter of 2024, confirming da Vinci 5 is capturing an increasing share of total placement activity. The effect on the market is that hospital capital investment in robotic-assisted minimally invasive surgery is accelerating beyond replacement-cycle-driven demand into genuine capacity expansion. These are some of the key factors driving revenue growth of the market.

“Intuitive Surgical placed 870 da Vinci 5 systems during 2025, more than double the 362 placed during 2024, out of 1,721 total da Vinci systems placed globally, confirming that the newest-generation robotic-assisted platform is capturing an accelerating share of total hospital capital investment in minimally invasive surgical capacity.”

The third driver is continued reimbursement policy support for robotic-assisted minimally invasive procedures performed at ambulatory surgical centres rather than only hospital inpatient settings. Ambulatory surgical centres cannot expand robotic-assisted procedure volume without adequate reimbursement covering both the procedure and the associated capital equipment cost, and CMS reimbursement policy expansion directly addresses this requirement for an increasing range of robotic-assisted orthopaedic and urological procedures, so reimbursement policy expansion and ambulatory surgical centre robotic-assisted procedure volume growth are directly linked. Continued CMS ambulatory surgical centre reimbursement expansion for robotic-assisted orthopaedic and urological procedures is extending the addressable site-of-care base for robotic-assisted minimally invasive surgery beyond traditional hospital inpatient and outpatient departments. The effect on the market is that robotic-assisted minimally invasive surgery procedure volume growth is increasingly supported by ambulatory surgical centre capacity expansion, not solely by continued hospital-based installed base growth. These are some of the key factors driving revenue growth of the market.

However, the minimally invasive surgery market faces adoption constraints from the high capital acquisition cost of robotic surgical systems, a shortage of trained minimally invasive surgery specialists that limits procedure volume scaling even where capital equipment is available, and procedure standardisation and outcomes data variability across the full range of minimally invasive surgery applications. Because robotic surgical systems require substantial upfront capital investment, with da Vinci 5 system list prices estimated well above the prior-generation da Vinci Xi platform, hospitals outside large academic and tertiary surgical centres in both developed and emerging markets face a genuine capital barrier that constrains robotic-assisted adoption penetration beyond these leading institutions, meaning installed base growth documented in Driver 1 above concentrates disproportionately among the hospitals best positioned to absorb this capital cost. Shortage of trained minimally invasive surgery specialists is a second constraint, because expanding robotic-assisted and advanced laparoscopic procedure volume requires a growing pool of surgeons credentialed in these techniques, and surgical training programme capacity, including robotic-assisted surgery fellowship and credentialing pathways, has not expanded as quickly as robotic surgical system installed base growth in many markets, creating a genuine bottleneck between system placement and full clinical utilisation. Procedure standardisation and outcomes data variability is the third constraint, since demonstrating consistent clinical and cost-effectiveness outcomes across the full range of minimally invasive surgery applications, spanning general surgery, orthopaedics, urology, and gynaecology, requires accumulating procedure-specific outcomes data that takes time to mature for newer robotic-assisted applications, and payers and hospital systems weighing new capital investment or reimbursement policy decisions depend on this maturing evidence base. These factors substantially limit minimally invasive surgery market growth over the forecast period.

Based on product type, the global minimally invasive surgery market is segmented into robotic-assisted surgical systems, laparoscopic/endoscopic devices, and surgical instruments and accessories. Surgical instruments and accessories hold the largest revenue share, because recurring per-procedure consumable revenue compounds against a growing installed base of both robotic-assisted and conventional laparoscopic systems, which suits the broader industry shift toward recurring revenue relative to one-time capital equipment sales. Robotic-assisted surgical systems are expected to register the fastest revenue growth rate in the global minimally invasive surgery market over the forecast period, driven directly by da Vinci 5’s accelerating placement pace, which is why capital equipment revenue growth is currently outpacing the broader market’s overall growth rate.

General and gastrointestinal surgery procedure type is expected to account for a significantly large revenue share in the global minimally invasive surgery market during the forecast period

Based on procedure type, the global minimally invasive surgery market is segmented into general and gastrointestinal surgery, orthopaedic and urological surgery, and gynaecologic and cardiothoracic surgery. General and gastrointestinal surgery holds a significant revenue share, reflecting the broad, established procedure volume base across abdominal surgical indications that both robotic-assisted and conventional laparoscopic technology serve. Orthopaedic and urological surgery is expected to register rapid revenue growth in the global minimally invasive surgery market over the forecast period, driven directly by CMS ambulatory surgical centre reimbursement expansion for robotic-assisted procedures in these specialties, which is why this procedure category represents one of the fastest-evolving reimbursement-driven growth areas.

Oncologic surgery application is expected to account for the largest revenue share in the global minimally invasive surgery market during the forecast period

Based on application, the global minimally invasive surgery market is segmented into oncologic surgery, bariatric and metabolic surgery, and reconstructive and orthopaedic surgery. Oncologic surgery holds the largest revenue share, reflecting the broad range of cancer surgical indications, from general and gastrointestinal to gynaecologic and thoracic cancers, that minimally invasive and robotic-assisted approaches increasingly address. Reconstructive and orthopaedic surgery is expected to register rapid revenue growth in the global minimally invasive surgery market over the forecast period, driven by expanding robotic-assisted orthopaedic procedure reimbursement and adoption, which is why this application represents a growing area of minimally invasive surgery expansion beyond its traditional soft-tissue surgical base.

Based on regional analysis, the minimally invasive surgery market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of the worldwide robotic-assisted surgical system installed base, and because CMS reimbursement policy expansion for robotic-assisted ambulatory surgical centre procedures directly shapes United States site-of-care economics. Intuitive Surgical placed 870 da Vinci 5 systems during 2025 with a substantial majority concentrated in the United States, reinforcing the country’s leading position in newest-generation robotic-assisted platform adoption. The concentration of both the largest robotic-assisted installed base and CMS reimbursement policy authority in the United States also means new minimally invasive surgery technology and reimbursement models are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national minimally invasive surgery markets within Europe. Da Vinci 5’s July 2025 CE mark approval extended the platform’s availability across the region, and the region’s established minimally invasive surgical infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature surgical infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national minimally invasive surgery markets within the region. Expanding robotic-assisted surgical system installed base growth and rising minimally invasive procedure adoption in China and India are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national minimally invasive surgery markets within the region. Private hospital networks in both countries are gradually expanding robotic-assisted surgical capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised surgical systems and instruments that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial minimally invasive surgery markets within the GCC. The UAE is the most established minimally invasive surgery market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the surgical infrastructure and specialist training capacity that robotic-assisted procedure adoption depends on.